Precision BioSciences, Inc. (DTIL)
After hours:
- Business Wire
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
DURHAM, N.C., May 08, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL) (the "Company"), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership team,
- Business Wire
Precision BioSciences to Report First Quarter Results on May 13, 2024
DURHAM, N.C., May 07, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.
- Business Wire
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
DURHAM, N.C., May 07, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that its partner iECURE has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ECUR-506. ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal onse
